A Bioconjugate Vaccine Against Extra-Intestinal Pathogenic <i>Escherichia coli</i> (ExPEC)
<b>Background</b>: Extra-intestinal pathogenic <i>Escherichia coli</i> (ExPEC) represents a major global public health challenge due to its ability to cause diverse clinical infections, including urinary tract infections, bacteremia, neonatal meningitis, and sepsis. The growi...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/4/362 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850180000666353664 |
|---|---|
| author | Linhui Hao Wenhua Huang Yan Guo Xiankai Liu Jun Wu Li Zhu Chao Pan Hengliang Wang |
| author_facet | Linhui Hao Wenhua Huang Yan Guo Xiankai Liu Jun Wu Li Zhu Chao Pan Hengliang Wang |
| author_sort | Linhui Hao |
| collection | DOAJ |
| description | <b>Background</b>: Extra-intestinal pathogenic <i>Escherichia coli</i> (ExPEC) represents a major global public health challenge due to its ability to cause diverse clinical infections, including urinary tract infections, bacteremia, neonatal meningitis, and sepsis. The growing prevalence of multidrug-resistant (MDR) ExPEC strains, which rapidly erode antibiotic efficacy, underscores vaccine development as a critical priority. Bioconjugate vaccines have emerged as a promising approach to mitigate ExPEC-associated infections. <b>Methods and Results</b>: In this study, we utilized protein glycan coupling technology (PGCT) based on oligosaccharyltransferase (OST) PglL to engineer a tetravalent bioconjugate vaccine targeting four predominant ExPEC serotypes (O1, O2, O6, and O25). We conducted a series of experiments to demonstrate the efficacy of the conjugate vaccine in eliciting humoral immune responses and inducing the production of specific antibodies against <i>Escherichia coli</i> O1, O2, O6, or O25 serotypes. <b>Conclusions</b>: This work establishes the first application of the <i>O</i>-linked PGCT system for engineering bioconjugate vaccines against ExPEC infections. |
| format | Article |
| id | doaj-art-dd66480cd91049fc88ecc755fb792e60 |
| institution | OA Journals |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-dd66480cd91049fc88ecc755fb792e602025-08-20T02:18:20ZengMDPI AGVaccines2076-393X2025-03-0113436210.3390/vaccines13040362A Bioconjugate Vaccine Against Extra-Intestinal Pathogenic <i>Escherichia coli</i> (ExPEC)Linhui Hao0Wenhua Huang1Yan Guo2Xiankai Liu3Jun Wu4Li Zhu5Chao Pan6Hengliang Wang7Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, ChinaState Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing 100071, ChinaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, ChinaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, ChinaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, ChinaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, ChinaLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, ChinaState Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing 100071, China<b>Background</b>: Extra-intestinal pathogenic <i>Escherichia coli</i> (ExPEC) represents a major global public health challenge due to its ability to cause diverse clinical infections, including urinary tract infections, bacteremia, neonatal meningitis, and sepsis. The growing prevalence of multidrug-resistant (MDR) ExPEC strains, which rapidly erode antibiotic efficacy, underscores vaccine development as a critical priority. Bioconjugate vaccines have emerged as a promising approach to mitigate ExPEC-associated infections. <b>Methods and Results</b>: In this study, we utilized protein glycan coupling technology (PGCT) based on oligosaccharyltransferase (OST) PglL to engineer a tetravalent bioconjugate vaccine targeting four predominant ExPEC serotypes (O1, O2, O6, and O25). We conducted a series of experiments to demonstrate the efficacy of the conjugate vaccine in eliciting humoral immune responses and inducing the production of specific antibodies against <i>Escherichia coli</i> O1, O2, O6, or O25 serotypes. <b>Conclusions</b>: This work establishes the first application of the <i>O</i>-linked PGCT system for engineering bioconjugate vaccines against ExPEC infections.https://www.mdpi.com/2076-393X/13/4/362extra-intestinal pathogenic <i>Escherichia coli</i> (ExPEC)bioconjugate vaccineprotein glycan coupling technology (PGCT)cholera toxin B subunit (CTB) |
| spellingShingle | Linhui Hao Wenhua Huang Yan Guo Xiankai Liu Jun Wu Li Zhu Chao Pan Hengliang Wang A Bioconjugate Vaccine Against Extra-Intestinal Pathogenic <i>Escherichia coli</i> (ExPEC) Vaccines extra-intestinal pathogenic <i>Escherichia coli</i> (ExPEC) bioconjugate vaccine protein glycan coupling technology (PGCT) cholera toxin B subunit (CTB) |
| title | A Bioconjugate Vaccine Against Extra-Intestinal Pathogenic <i>Escherichia coli</i> (ExPEC) |
| title_full | A Bioconjugate Vaccine Against Extra-Intestinal Pathogenic <i>Escherichia coli</i> (ExPEC) |
| title_fullStr | A Bioconjugate Vaccine Against Extra-Intestinal Pathogenic <i>Escherichia coli</i> (ExPEC) |
| title_full_unstemmed | A Bioconjugate Vaccine Against Extra-Intestinal Pathogenic <i>Escherichia coli</i> (ExPEC) |
| title_short | A Bioconjugate Vaccine Against Extra-Intestinal Pathogenic <i>Escherichia coli</i> (ExPEC) |
| title_sort | bioconjugate vaccine against extra intestinal pathogenic i escherichia coli i expec |
| topic | extra-intestinal pathogenic <i>Escherichia coli</i> (ExPEC) bioconjugate vaccine protein glycan coupling technology (PGCT) cholera toxin B subunit (CTB) |
| url | https://www.mdpi.com/2076-393X/13/4/362 |
| work_keys_str_mv | AT linhuihao abioconjugatevaccineagainstextraintestinalpathogeniciescherichiacoliiexpec AT wenhuahuang abioconjugatevaccineagainstextraintestinalpathogeniciescherichiacoliiexpec AT yanguo abioconjugatevaccineagainstextraintestinalpathogeniciescherichiacoliiexpec AT xiankailiu abioconjugatevaccineagainstextraintestinalpathogeniciescherichiacoliiexpec AT junwu abioconjugatevaccineagainstextraintestinalpathogeniciescherichiacoliiexpec AT lizhu abioconjugatevaccineagainstextraintestinalpathogeniciescherichiacoliiexpec AT chaopan abioconjugatevaccineagainstextraintestinalpathogeniciescherichiacoliiexpec AT hengliangwang abioconjugatevaccineagainstextraintestinalpathogeniciescherichiacoliiexpec AT linhuihao bioconjugatevaccineagainstextraintestinalpathogeniciescherichiacoliiexpec AT wenhuahuang bioconjugatevaccineagainstextraintestinalpathogeniciescherichiacoliiexpec AT yanguo bioconjugatevaccineagainstextraintestinalpathogeniciescherichiacoliiexpec AT xiankailiu bioconjugatevaccineagainstextraintestinalpathogeniciescherichiacoliiexpec AT junwu bioconjugatevaccineagainstextraintestinalpathogeniciescherichiacoliiexpec AT lizhu bioconjugatevaccineagainstextraintestinalpathogeniciescherichiacoliiexpec AT chaopan bioconjugatevaccineagainstextraintestinalpathogeniciescherichiacoliiexpec AT hengliangwang bioconjugatevaccineagainstextraintestinalpathogeniciescherichiacoliiexpec |